ABSTRACT
The early 1990s witnessed the birth of many new biotechnology companies, some of which were funded to operate small molecule drug discovery programs. In the preceding years, major pharmaceutical and established biotechnology companies began exploiting ever expanding chemical libraries as sources of new chemical leads for their therapeutic targets. Widespread changes in high throughput screening (HTS) technology have enabled companies to screen hundreds of thousands of samples per year against multiple screening targets.
